Clinical Questions in Cardiology: Using Glucagon-like Peptide-1 Receptor Agonists

To participate in this activity, please:

Diabetes is a chronic metabolic disorder with multiple complications [including  cardiovascular (CV) disease] which negatively impact patients and the healthcare system. In large part due to the lack of clarity on antihyperglycemic agents’ effect on CV risk, the US Food and Drug Administration (FDA) mandated CV outcomes trials (CVOTs) to assess the CV safety of novel glucose-lowering agents. Among these many CVOTs, the class of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) were elevated in clinical practice as some GLP-1 RAs showcased substantial CV and renal benefits. These benefits are now reflected in several evidence-based guidelines as well in the FDA package inserts for dulaglutide, liraglutide, and injectable semaglutide. Despite the availability of this information, there are many gaps in practice among cardiologists pertaining to confidence and application of this knowledge to utilize GLP-1 RAs in patients with type 2 diabetes and atherosclerotic cardiovascular disease (ASCVD). These current challenges related to GLP-1 RA therapy will be highlighted in this program, including glycemic and extra-glycemic effects, familiarity with recent evidence-based guidelines and CVOTs, and adverse event education and management. Through this clinical activity, with the guidance of key clinical questions answered by expert faculty, there will be improvement in clinician understanding of the efficacy, safety, profile, and roles of GLP-1 RAs, utilization of treatment guidelines and literature, and implementation of GLP-1 RA therapy to optimize and individualize care in patients with T2D and ASCVD. 

Course Credit:

1 AMA PRA Category 1 CreditTM


Opens: 2023-11-18
Closes: 2023-11-28

Target Audience:

The target audience includes regional and national audiences of cardiologists and cardiology advanced practice providers who treat patients with type 2 diabetes (T2D), and other clinicians with an interest in T2D.

This activity is supported by an independent educational grant from Novo Nordisk.

    Presenting Faculty

  • Jorge Plutzky, MD

    Director, Preventive Cardiology
    Cardiovascular Medicine
    Brigham and Women's Hospital
    Boston, Massachusetts

  • Helena W. Rodbard, MD

    Past President, American Association of Clinical Endocrinologists (AACE)
    Past President, American College of Endocrinology (ACE)
    Founder and Medical Director, Endocrine and Metabolic Consultants
    Rockville, Maryland